Get started
Author

Émeline Tabouret

Observed names: E TABOURET, E Tabouret, E. Tabouret, E., Tabouret, EMELINE TABOURET, Emeline Tabouret, Emmeline Tabouret, Tabouret E, Tabouret Emeline, Tabouret, E., Tabouret, Emeline, Tabouret, Emeline; https://orcid.org/0000-0002-4031-2178, émeline Tabouret
Observed institutions: Centre National de la Recherche Scientifique, National Institutes of Health, University of Bonn, Inserm, Aix-Marseille Université, Sorbonne Université, Institut des Sciences Moléculaires, Assistance Publique Hôpitaux de Marseille, Assistance Publique – Hôpitaux de Paris, Institut de Neurophysiopathologie, Centre Hospitalier Régional et Universitaire de Nancy, Hospices Civils de Lyon, Centre Léon Bérard, Centre Hospitalier Universitaire de Caen Normandie, Pitié-Salpêtrière Hospital, Institut Fresnel, Hôpital Avicenne, National Cancer Institute, Centrale Méditerranée, Centre de Recherche en Cancérologie de Marseille, Center for Cancer Research, Institut Paoli-Calmettes, Institut du Cerveau, Hôpital de la Timone, Université Pierre-et-Marie-Curie, Medical University of Vienna
ORCID: 0000-0002-4031-2178
Observed ORCID: 0000-0002-4031-2178
OpenAlex ID: A5059620448
SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution
2020 · Rafael J. Argüello, Alexis J. Combes, et al. · Cell Metabolism · 581
PDF
Recent trends in epidemiology of brain metastases: an overview.
2012 · Emeline Tabouret, Olivier Chinot, et al. · PubMed · 355
Challenges in glioblastoma research: focus on the tumor microenvironment
2022 · Andreas Bikfalvi, Cristine Alves da Costa, et al. · Trends in cancer · 304
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas
2019 · Romain Appay, Caroline Dehais, et al. · Neuro-Oncology · 278
PDF
Management and outcome of primary CNS lymphoma in the modern era
2020 · Caroline Houillier, Carole Soussain, et al. · Neurology · 247
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
2024 · Justin Z Wang, Alexander P Landry, et al. · Neuro-Oncology · 156
PDF
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
2020 · Thomas Graillon, Marc Sanson, et al. · Clinical Cancer Research · 144
PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas
2019 · R Appay, C Dehais, et al. · Neuro-Oncology · 125
PDF
Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort
2016 · For POLA Network, Emeline Tabouret, et al. · Acta Neuropathologica · 110
Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling
2016 · Dominique Figarella-Branger, Emmanuèle Lechapt-Zalcman, et al. · Neuro-Oncology · 96
PDF
Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
2023 · Caroline Hertler, Jörg Felsberg, et al. · European Journal of Cancer · 82
PDF
FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan
2012 · C. Colavolpe, O. Chinot, et al. · Neuro-Oncology · 80
Reassessment of scoring systems and prognostic factors for metastatic spinal cord compression
2013 · Emeline Tabouret, Cécile Cauvin, et al. · The Spine Journal · 79
Clinical Management of Diffuse Low-Grade Gliomas
2020 · Giuseppe Lombardi, Valeria Barresi, et al. · Cancers · 76
PDF
Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults
2021 · Thiébaud Picart, Marc Barritault, et al. · Neuro-Oncology Advances · 75
PDF
Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads
2018 · Karine Baumstarck, Olivier Chinot, et al. · Health and Quality of Life Outcomes · 70
PDF
LRP1B deletion is associated with poor outcome for glioblastoma patients
2015 · E. Tabouret, M. Labussière, et al. · Journal of the Neurological Sciences · 67
Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial
2016 · E. Tabouret, C. Houillier, et al. · Neuro-Oncology · 64
PDF
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
2013 · Emeline Tabouret, Françoise Boudouresque, et al. · Neuro-Oncology · 64
PDF
Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study
2021 · Marion Lam, Valérie Touitou, et al. · American Journal of Hematology · 60
PDF
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway
2015 · Emeline Tabouret, Aurelie Tchoghandjian, et al. · Oncotarget · 58
PDF
Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
2022 · Giuseppe Lombardi, Pietro Luigi Poliani, et al. · Cancers · 57
PDF
MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma
2015 · Emeline Tabouret, Françoise Boudouresque, et al. · Neuro-Oncology · 56
Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152
2016 · A Tchoghandjian, A Soubéran, et al. · Cell Death and Disease · 51
PDF
Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
2022 · Carine Jiguet-Jiglaire, Sebastien Boissonneau, et al. · Acta Neuropathologica Communications · 50
PDF
Works count: 271
Citation count: 4,740
H-index: 33
I10-index: 78
Year
Topic
Type